ClinicalTrials.gg
Not yet recruitingNCT07588373LS-LP-CHUpdated May 14, 2026

Effect of Laparoscopic Splenectomy on Lipid Profiles in Cirrhotic Patients With Hypersplenism (2-Year Follow-Up)

An observational study in Cirrhosis, Splenectomy; Status and Hypersplenism, sponsored by Northern Jiangsu People's Hospital. Not yet recruiting at 1 site in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-05-14.

Primary conditionFibrosis(the registry's first term)UnverifiedIs this wrong?Fibrosis is a broad heading, used only when no more specific condition is named. No better condition is named, so the registry's term is kept.

Sponsored by Northern Jiangsu People's Hospital · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
30
Ages
18 Years to 80 Years
Sex
All
01

Study summary

Patients with liver cirrhosis frequently exhibit dyslipidemia due to impaired hepatic lipid synthesis, altered bile acid metabolism, and portal hypertension. Laparoscopic splenectomy is commonly used to treat splenomegaly and hypersplenism in these patients, but its impact on lipid profiles over 2 years remains poorly characterized. This study will follow patients undergoing laparoscopic splenectomy to measure changes in serum lipid parameters before and after surgery, identify risk factors for lipid profile deterioration or improvement, and determine whether laparoscopic splenectomy can ameliorate dyslipidemia in the long term, thereby informing metabolic management strategies in cirrhotic patients.

Read the detailed description

Rationale: Liver cirrhosis disrupts hepatic lipid homeostasis through multiple mechanisms, including decreased apolipoprotein synthesis, impaired cholesterol esterification, and altered very-low-density lipoprotein (VLDL) secretion, resulting in characteristic lipid abnormalities such as hypocholesterolemia and low high-density lipoprotein cholesterol (HDL-C). Hypersplenism further complicates this metabolic profile through increased lipid peroxidation and inflammatory cytokine-mediated dysregulation of lipid metabolism. Laparoscopic splenectomy (LS) reduces splenic sequestration and inflammatory burden, potentially improving hepatic lipid synthetic capacity and peripheral lipid clearance. However, perioperative stress responses, anesthetic effects, and abrupt hemodynamic changes may transiently worsen lipid profiles. Current evidence lacks prospective, 2-year data on lipid profile dynamics after LS in this population, particularly regarding the trajectory of total cholesterol, triglycerides, LDL-C, HDL-C. This study aims to fill this gap to guide perioperative metabolic monitoring and long-term dyslipidemia management.

Study Design: Prospective, single-center, observational cohort study with a total duration of 24 months (2 years). Patients with cirrhosis, splenomegaly and hypersplenism scheduled for elective laparoscopic splenectomy will be enrolled and followed for 2 years to assess lipid profile dynamics and identify risk factors for metabolic deterioration or improvement.

Study Timeline:

Months 1-6: Patient screening, enrollment, baseline lipid assessment Months 1-18: Laparoscopic splenectomy and perioperative short-term lipid monitoring Months 7-24: Long-term follow-up at 3, 6, 9,12, 24 months postoperatively Month 24: Data analysis and study completion

02

Conditions studied

  • Cirrhosis
  • Splenectomy; Status
  • Hypersplenism
  • Lipid Profiles

Browse trials for

Keywords

  • Cirrhosis
  • Splenectomy
  • Laparoscopy
  • Lipid Profiles
  • Hypersplenism
  • portal hypertension
03

In context

Fibrosis Unverified

1,272 studies on the registry are indexed under Fibrosis; 278 are open to participants now.

This study's planned enrollment of 30 is below the median of 157 across 386 observational studies indexed under Fibrosis.

Browse Fibrosis studies →

Lead sponsor

Northern Jiangsu People's Hospital is the lead sponsor of 61 studies on the registry; 31 are open to participants now.

Compared within Fibrosis, the registry's first condition term, which may not be this study's main condition. Counted across the registry records on this site, refreshed daily. How we classify →

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

A 24-month (2-year) prospective, single-center, observational cohort study. Patients with liver cirrhosis and hypersplenism scheduled for elective laparoscopic splenectomy will be recruited and followed up for 2 years to evaluate dynamic changes in lipid profiles.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age 18-80 years, male or female
  2. Confirmed diagnosis of liver cirrhosis (clinical, laboratory, imaging)
  3. Splenomegaly and hypersplenism
  4. Class A or B liver function
  5. Signed written
  6. Ability to complete 24-month follow-up

Exclusion criteria

Exclusion Criteria:

  1. Class C liver cirrhosis
  2. No history of portal hypertension bleeding (esophageal and gastric variceal bleeding )
  3. Previous abdominal surgery precluding safe laparoscopic splenectomy.
  4. Severe cardiac, pulmonary, cerebrovascular dysfunction; malignant tumors; primary hematological disorders
  5. Metabolic/endocrine diseases: Familial hyperlipidemia; uncontrolled severe diabetes mellitus, thyroid dysfunction, nephrotic syndrome; use of lipid-lowering drugs, hormones, or other drugs affecting blood lipids within 1 month before surgery.
  6. Infections/inflammatory diseases: Active hepatitis, severe infections, or diseases.
  7. Cirrhotic complications (hepatic encephalopathy, ascites) within 1 month before surgery
  8. Pregnancy or lactation
  9. Poor compliance, inability to complete follow-up
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
30 participants (estimated)
Target follow-up
2 Years
Patient registry
Yes
06

What researchers measure

Primary outcomes

  1. Total cholesterol (TC) level

    Change in total cholesterol (TC) level

    Time frame: at preoperative baseline, postoperative month 1, month 3, month 6, month 12, month 18, month 24

  2. Total triglycerides (TG) level

    Change in total triglycerides (TG) level

    Time frame: at preoperative baseline, postoperative month 1, month 3, month 6, month 12, month 18, month 24

  3. High-density lipoprotein cholesterol (HDL-C) level

    Change in high-density lipoprotein cholesterol (HDL-C)

    Time frame: at preoperative baseline, postoperative month 1, month 3, month 6, month 12, month 18, month 24

  4. Low-density lipoprotein cholesterol (LDL-C) level

    Change in low-density lipoprotein cholesterol (LDL-C)

    Time frame: at preoperative baseline, postoperative month 1, month 3, month 6, month 12, month 18, month 24

Secondary outcomes

  1. Intraoperative variables

    operation time, intraoperative blood loss, fluid infusion, mean arterial pressure

    Time frame: During the procedure of operation

  2. Postoperative complications

    postoperative complications (bleeding, infection, hepatic encephalopathy, ascites)

    Time frame: at preoperative baseline, postoperative month 1, month 3, month 6, month 12, month 18, month 24

  3. Albumin, bilirubin

    Changes in albumin, bilirubin

    Time frame: at preoperative baseline, postoperative month 1, month 3, month 6, month 12, month 18, month 24

  4. Child-Pugh grade

    Changes in Child-Pugh grade The Child-Pugh score is calculated based on five parameters, each assigned 1, 2, or 3 points. 1. Total bilirubin * Less than 2 mg/dL: 1 point * 2-3 mg/dL: 2 points * Greater than 3 mg/dL: 3 points 2. Serum albumin * Greater than 3.5 g/dL: 1 point * 2.8-3.5 g/dL: 2 points * Less than 2.8 g/dL: 3 points 3. Prothrombin time prolongation or INR * Prolongation less than 4 seconds (INR \< 1.7): 1 point * Prolongation 4-6 seconds (INR 1.7-2.3): 2 points * Prolongation greater than 6 seconds (INR \> 2.3): 3 points 4. Ascites * None: 1 point * Mild or controlled with diuretics: 2 points * Moderate to severe or refractory: 3 points 5. Hepatic encephalopathy * None: 1 point * Grade I-II: 2 points * Grade III-IV: 3 points Total score and corresponding grade * 5-6 points: Child-Pugh class A * 7-9 points: Child-Pugh class B * 10-15 points: Child-Pugh class C

    Time frame: at preoperative baseline, postoperative month 1, month 3, month 6, month 12, month 18, month 24

07

Study locations

1 site
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for May 2026; primary completion for Feb 2029, 33 months later.

Of 177 non-industry observational studies under Fibrosis, half reached primary completion within 54 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 105. This study's planned 33 months is below that.

Counting every sponsor, half of 186 studies reached it within 49 months; a quarter within 22 and three quarters within 87.

How these figures are worked out, and which studies are left out of them.

Registered
May 1, 2026
First posted
May 14, 2026
StartEst.
May 1, 2026
Primary completionEst.
Feb 28, 2029
CompletionEst.
Feb 28, 2029
Last update
May 14, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 14, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07588373
Lead sponsor
Northern Jiangsu People's Hospital
Responsible party
Guo-Qing Jiang (Clinical Professor, Northern Jiangsu People's Hospital) — Principal investigator
First posted
May 14, 2026
Start date
May 1, 2026 (estimated)
Primary completion
Feb 28, 2029 (estimated)
Completion
Feb 28, 2029 (estimated)
Last update
May 14, 2026

Study contacts

Guo-Qing Jiang, MD
Contact
jgqing2003@hotmail.com
+8651487373272
Dou-Sheng Bai, MD
Contact
bdsno1@hotmail.com
+8651487373372
Guo-Qing Jiang, MD
study chair · Clinical Medical College of Yangzhou University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion